| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.62M | 7.62M | 7.23M | 4.98M | 4.43M | 735.44K |
| Gross Profit | 1.50M | 1.50M | 6.74M | -2.44M | 4.14M | -2.03M |
| EBITDA | 275.62K | 275.62K | -826.62K | -2.65M | -5.90M | -5.06M |
| Net Income | -72.20K | -72.20K | -2.67M | -4.33M | -5.25M | -5.23M |
Balance Sheet | ||||||
| Total Assets | 5.94M | 5.94M | 6.82M | 7.57M | 8.02M | 12.23M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 1.05M | 1.25M | 1.85M | 4.50M | 8.90M |
| Total Debt | 2.37M | 2.37M | 192.98K | 961.96K | 0.00 | 75.28K |
| Total Liabilities | 4.42M | 4.42M | 3.30M | 4.02M | 1.72M | 2.61M |
| Stockholders Equity | 1.52M | 1.52M | 1.97M | 2.14M | 6.30M | 9.61M |
Cash Flow | ||||||
| Free Cash Flow | -804.93K | -804.93K | -2.59M | -3.42M | -4.54M | -1.52M |
| Operating Cash Flow | -732.06K | -732.06K | -1.30M | -2.53M | -4.52M | -1.50M |
| Investing Cash Flow | 119.16K | 119.16K | -570.80K | -799.63K | -256.83K | -23.21K |
| Financing Cash Flow | 370.14K | 400.96K | 1.27M | 687.55K | 8.81M | 1.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$61.66M | -6.75 | -8647.54% | ― | 25.98% | 22.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | ― | -36.67 | 3.02% | ― | 5.42% | 97.46% | |
41 Neutral | AU$4.93M | -5.64 | ― | ― | -9.90% | 34.07% | |
40 Underperform | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$80.06M | -11.23 | ― | ― | ― | ― | |
34 Underperform | AU$14.30M | -5.21 | ― | ― | 241.34% | 44.19% |
Careteq Limited announced that all resolutions were passed at its 2025 Annual General Meeting. This outcome reflects positively on the company’s governance and may strengthen its position in the healthtech industry, potentially benefiting stakeholders by reinforcing confidence in its strategic direction.
Careteq Limited has amended its Q1 FY26 Appendix 4C to include previously omitted details about its financing facilities, specifically loan agreements with directors and outstanding convertible notes. The company emphasizes its commitment to accurate and timely market disclosures, reflecting its current financing structure and maintaining transparency with stakeholders.
Careteq Limited has reported its Q1 FY26 activities, highlighting growth in its Embedded Health Solutions (EHS) with facilities under contract nearing 600 and aged-care beds increasing by 3% for the quarter. Despite facing operational cash outflows and one-off costs related to an ATO R&D matter, the company remains optimistic about its sales pipeline and has engaged a specialist firm to expedite the integration of its 1-System platform, expected to recommence in Q3 FY26. This strategic move aims to enhance operational efficiencies and support continued growth.